A new research study has shown that pancreatic cancer cells can be coaxed to revert back toward normal cells by introducing a protein called E47.
E47 binds to specific DNA sequences and controls genes involved in growth and differentiation. The research provides hope for a new treatment approach for the more than 40,000 people who die from the disease each year in the United States.
“For the first time, we have shown that overexpression of a single gene can reduce the tumor-promoting potential of pancreatic adenocarcinoma cells and reprogram them toward their original cell type. Thus, pancreatic cancer cells retain a genetic memory which we hope to exploit,” said Pamela Itkin-Ansari, Ph.D., adjunct professor in the Development, Aging, and Regeneration Program at Sanford-Burnham and lead author of the study published today in the journal Pancreas.
E47 turns the clock back
The study, a collaborative effort between Sanford-Burnham, UC San Diego, where Itkin-Ansari holds a joint appointment, and Purdue University, generated human pancreatic ductal adenocarcinoma cell lines to make higher-than-normal levels of E47. The increased amount of E47 caused cells to stall in the G0/G1 growth phase, and differentiate back toward an acinar cell phenotype.
In-vivo studies showed that when the reprogrammed cancer cells were introduced into mice, their ability to form tumors was greatly diminished compared to untreated adenocarcinoma cells.
“Presently, pancreatic adenocarcinoma is treated with cytotoxic agents, yet the average survival for patients post-diagnosis is merely six months, and the improvements in therapies are measured in days,” said Andrew M. Lowy, M.D., professor of surgery at the UC San Diego Moores Cancer Center and co-chair of the National Cancer Institute’s Pancreatic Cancer Task Force. “The finding that we can differentiate these cancer cells back to a non-threatening phenotype is encouraging. Indeed, there is a precedent for cell differentiation therapy in that the approach has been used to treat acute promyelocytic leukemia (APL) and some neuroblastomas successfully.”
“Our next step is to test primary patient-derived tumor tissue to determine whether E47 can produce similar results, potentially providing a novel therapeutic approach to combating this highly lethal disease,” said Itkin-Ansari. “Additionally, we are screening for molecules—potential drugs—that can induce overexpression of E47.”
The Latest on: Pancreatic cancer
via Google News
The Latest on: Pancreatic cancer
- Stoughton Police Dispatcher Dies After Battle With Canceron August 10, 2020 at 1:31 pm
Dispatch supervisor Carl Fischer vowed to see his sons graduate high school before his passing, and he kept that promise.
- PharmaCyte Biotech Appoints Dr. José Iglesias as Consulting Chief Medical Officer for Clinical Trial in Pancreatic Canceron August 10, 2020 at 6:19 am
PharmaCyte Biotech appoints Dr. Jose Iglesias as Consulting Chief Medical Officer for clinical trial in pancreatic cancer.
- Pancreatic Cancer Market in Global Industry: Demands, Insights, Research and Forecast 2020-2026on August 10, 2020 at 5:00 am
Pancreatic cancer is origins by the unrestrained boom of cells within the pancreas. This atypical, uncontrolled boom of ...
- How a protein promotes pancreatic cancer metastasison August 7, 2020 at 2:47 am
While studying how pancreatic cancer adapts to a low-oxygen environment, scientists at Sanford Burnham Prebys Medical Discovery Institute uncovered a protein that appeared to be driving tumor ...
- Hoag Offers Clinical Trial for Pancreatic Cancer Patientson August 5, 2020 at 11:28 am
Hoag Memorial Hospital Presbyterian has been selected to conduct a Phase 2 clinical trial that researchers hope will demonstrate ...
- Scientists discover novel drug target for pancreatic canceron August 5, 2020 at 8:51 am
Scientists at Sanford Burnham Prebys Medical Discovery Institute have uncovered a novel drug target, a protein called PPP1R1B, that stops the deadly spread of pancreatic cancer, called metastasis, ...
- Hopes of new pancreatic cancer drug after mice treated in surprise scientific discoveryon August 5, 2020 at 7:01 am
Scientists have discovered a protein that they believe makes pancreatic cancer “so lethal”. Pancreatic cancer is the tenth most common form of the disease in the UK, with 28 patients being diagnosed ...
- Pancreatic Cancer Action Network Appoints New Leadership And Members To Its Board Of Directorson August 4, 2020 at 10:11 pm
Pancreatic Cancer Action Network Appoints New Leadership And Members To Its Board Of Directors PR Newswire MANHATTAN BEACH, Calif., Aug. 4, 2020 Strategic Leadership Will Support Innovation and ...
- Screening for pancreatic cancer using artificial intelligenceon August 3, 2020 at 2:38 am
Medical about her research into how pancreatic cancer prognosis could be improved by using artificial intelligence.
- Comment on: ‘Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients’on August 2, 2020 at 3:08 pm
In their recent article on biomarker-based risk of pancreatic cancer, 1 the authors analyse the potential value of Trefoil protein 1 (TFF1) as a component of a PancRISK panel. Our ...
via Bing News